Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib

BACKGROUND: Crizotinib is associated with a favorable survival benefit in patients with ALK‐positive non‐small cell lung cancer (NSCLC); however, a subset of patients harboring ALK rearrangement shows a poor response. METHODS: We collected the clinical features and survival outcomes of 28 primary‐re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Di, Zhang, Yan, Xing, Puyuan, Hao, Xuezhi, Wang, Mengzhao, Wang, Yan, Shan, Li, Xin, Tao, Liang, Hongge, Du, Yang, Zhang, Zhaohui, Liang, Li, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500990/
https://www.ncbi.nlm.nih.gov/pubmed/30993895
http://dx.doi.org/10.1111/1759-7714.13071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500990/
https://www.ncbi.nlm.nih.gov/pubmed/30993895
http://dx.doi.org/10.1111/1759-7714.13071

Ejemplares similares